Repligen (NASDAQ:RGEN) Downgraded to Sell Rating by StockNews.com

StockNews.com cut shares of Repligen (NASDAQ:RGEN) from a hold rating to a sell rating in a research report report published on Thursday.

Several other equities analysts have also issued reports on RGEN. TD Cowen assumed coverage on Repligen in a research note on Monday, February 10th. They issued a “buy” rating and a $200.00 target price on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $180.00 price objective on shares of Repligen in a research report on Friday, February 21st. Canaccord Genuity Group decreased their target price on shares of Repligen from $170.00 to $150.00 and set a “hold” rating for the company in a research report on Wednesday. Evercore ISI assumed coverage on shares of Repligen in a report on Tuesday, March 18th. They issued an “in-line” rating and a $155.00 price target on the stock. Finally, JPMorgan Chase & Co. upped their price target on Repligen from $190.00 to $200.00 and gave the stock an “overweight” rating in a research report on Friday, February 21st. One analyst has rated the stock with a sell rating, six have assigned a hold rating and eight have given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $176.82.

Repligen Trading Down 1.6 %

NASDAQ:RGEN opened at $130.00 on Thursday. The company has a debt-to-equity ratio of 0.26, a quick ratio of 8.76 and a current ratio of 10.44. The firm has a 50-day simple moving average of $140.76 and a 200-day simple moving average of $145.82. Repligen has a one year low of $102.97 and a one year high of $182.52. The firm has a market cap of $7.30 billion, a P/E ratio of -254.90, a P/E/G ratio of 4.54 and a beta of 1.27.

Repligen (NASDAQ:RGEN) last posted its earnings results on Thursday, February 20th. The biotechnology company reported $0.44 earnings per share for the quarter, topping analysts’ consensus estimates of $0.41 by $0.03. Repligen had a positive return on equity of 4.21% and a negative net margin of 4.64%. The company had revenue of $167.55 million during the quarter, compared to analyst estimates of $167.58 million. Equities analysts anticipate that Repligen will post 1.72 EPS for the current fiscal year.

Insider Buying and Selling at Repligen

In other news, Director Margaret Pax bought 250 shares of the firm’s stock in a transaction that occurred on Monday, March 17th. The stock was purchased at an average price of $150.69 per share, with a total value of $37,672.50. Following the completion of the acquisition, the director now directly owns 1,043 shares of the company’s stock, valued at $157,169.67. This trade represents a 31.53 % increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 1.20% of the company’s stock.

Hedge Funds Weigh In On Repligen

A number of institutional investors have recently bought and sold shares of RGEN. Stifel Financial Corp raised its holdings in shares of Repligen by 5.4% during the third quarter. Stifel Financial Corp now owns 4,404 shares of the biotechnology company’s stock worth $655,000 after purchasing an additional 226 shares during the last quarter. MML Investors Services LLC grew its position in Repligen by 2.7% during the 3rd quarter. MML Investors Services LLC now owns 3,383 shares of the biotechnology company’s stock worth $503,000 after purchasing an additional 89 shares during the period. Sanctuary Advisors LLC purchased a new position in shares of Repligen during the 3rd quarter valued at about $233,000. Tidal Investments LLC lifted its holdings in shares of Repligen by 142.8% in the 3rd quarter. Tidal Investments LLC now owns 11,149 shares of the biotechnology company’s stock valued at $1,659,000 after buying an additional 6,558 shares during the period. Finally, Peapack Gladstone Financial Corp purchased a new stake in shares of Repligen in the third quarter worth about $296,000. 97.64% of the stock is owned by hedge funds and other institutional investors.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.